File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: T, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells

TitleT, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells
Authors
Issue Date1-Apr-2023
PublisherElsevier
Citation
Differentiation, 2023, v. 130, p. 51-57 How to Cite?
Abstract

Adaptive cellular immunotherapy, especially chimeric antigen receptor-T (CAR-T) cell therapy, has advanced the treatment of hematological malignancy. However, major limitations still remain in the source of cells comes from the patients themselves. The use of human pluripotent stem cells to differentiate into immune cells, such as T cells, NK cells, and macrophages, then arm with chimeric antigen receptor (CAR) to enhance tumor killing has gained major attention. It is expected to solve the low number of immune cells recovery from patients, long waiting periods, and ethical issues(reprogramming somatic cells to produce induced pluripotent stem cells (iPS cells) avoids the ethical issues unique to embryonic stem cells (Lo and Parham, 2009). However, there are still major challenges to be further solved. This review summarizes the progress, challenges, and future direction in human pluripotent stem cell-based immunotherapy. 


Persistent Identifierhttp://hdl.handle.net/10722/331444
ISSN
2023 Impact Factor: 2.2
2023 SCImago Journal Rankings: 0.619
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHang, Su-
dc.contributor.authorWang, Nan-
dc.contributor.authorSugimura, Ryohichi-
dc.date.accessioned2023-09-21T06:55:48Z-
dc.date.available2023-09-21T06:55:48Z-
dc.date.issued2023-04-01-
dc.identifier.citationDifferentiation, 2023, v. 130, p. 51-57-
dc.identifier.issn0301-4681-
dc.identifier.urihttp://hdl.handle.net/10722/331444-
dc.description.abstract<p>Adaptive cellular immunotherapy, especially chimeric antigen receptor-T (CAR-T) cell therapy, has advanced the treatment of hematological malignancy. However, major limitations still remain in the source of cells comes from the patients themselves. The use of human pluripotent stem cells to differentiate into <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/immunocompetent-cell" title="Learn more about immune cells from ScienceDirect's AI-generated Topic Pages">immune cells</a>, such as T cells, NK cells, and macrophages, then arm with <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/chimeric-antigen-receptor" title="Learn more about chimeric antigen receptor from ScienceDirect's AI-generated Topic Pages">chimeric antigen receptor</a> (CAR) to enhance tumor killing has gained major attention. It is expected to solve the low number of immune cells recovery from patients, long waiting periods, and ethical issues(reprogramming <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/somatic-cell" title="Learn more about somatic cells from ScienceDirect's AI-generated Topic Pages">somatic cells</a> to produce <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/induced-pluripotent-stem-cell" title="Learn more about induced pluripotent stem cells from ScienceDirect's AI-generated Topic Pages">induced pluripotent stem cells</a> (iPS cells) avoids the ethical issues unique to <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/embryonic-stem-cell" title="Learn more about embryonic stem cells from ScienceDirect's AI-generated Topic Pages">embryonic stem cells</a> (<a href="https://www.sciencedirect.com/science/article/pii/S0301468123000014?via%3Dihub#bib49">Lo and Parham, 2009</a>). However, there are still major challenges to be further solved. This review summarizes the progress, challenges, and future direction in human pluripotent stem cell-based immunotherapy.<span> </span></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofDifferentiation-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleT, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells-
dc.typeArticle-
dc.identifier.doi10.1016/j.diff.2023.01.001-
dc.identifier.scopuseid_2-s2.0-85147376223-
dc.identifier.volume130-
dc.identifier.spage51-
dc.identifier.epage57-
dc.identifier.eissn1432-0436-
dc.identifier.isiWOS:000934960000001-
dc.identifier.issnl0301-4681-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats